Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Highly Selective Irreversible ITK Inhibitor Cpi-818 Reduces Acute Graft-Versus Host Disease

Sarah Lindner, Nicole Lee, Gabriel K Armijo, Marina D Burgos da Silva, Pamela S Herrera, Chi L Nguyen, Emmanuel A Dwomoh, Romina Ghale, Melody Smith, Miguel-Angel Perales, Kate A Markey, Joseph J Buggy, James W Janc, Marcel van den Brink

Blood (2021) 138 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2021-153360

Published: 2021

Journal Articles

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Michael S. Khodadoust, MD PhD, Tatyana A. Feldman, MD, Dok Hyun Yoon, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Dejan Radeski, MBBS, FRACP, FRCPA, Youn H. Kim, MD, Neha Mehta-Shah, MD, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Ryan A. Wilcox, MD, Won Seog Kim, MD PhD, Steven M. Horwitz, MD, Joseph J. Buggy, PhD, Andrew Hotson, PhD, Craig M. Hill, PhD, Brian Munneke, PhD, Suresh Mahabhashyam, MD, Richard A. Miller, MD, James W. Janc, PhD, Mehrdad Mobasher, MDMPH

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-137782

Published: 2020

Journal Articles

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

V. Koneti Koneti Rao, MD FRCPA, Patrick P. Ng, PhD, Craig M. Hill, PhD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137631

Published: 2020

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD MPH, Richard A. Miller, MD, James W. Janc, PhD, Long Kwei, PhD, Joseph J. Buggy, PhD, Gabriel Luciano, Anahita Mohammady, PharmD, Won Seog Kim, MD PhD, Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Steven M. Horwitz, MD, Dejan Radeski, MBBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4030.

https://doi.org/10.1182/blood-2019-124958

Published: 2019

Journal Articles

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

John C. Reneau, MD, Steven R. Hwang, MD, Carlos A. Murga-Zamalloa, MD, Joseph J. Buggy, PhD, James W. Janc, PhD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 4172.

https://doi.org/10.1182/blood-2018-99-110554

Published: 2018

Journal Articles

In Vivo Evidence That Ibrutininb Deregulates Chemokine Receptor CXCR4 Surface Membrane Expression and Signaling, Along with Inhibiting B Cell Antigen Receptor Signaling, As Causes for Defective Homing and Impaired Retention of CLL Cells in Tissues

Shih-Shih Chen, PhD, Betty Y. Chang, Stella Chang, Timothy Tong, Yong-Rui Zou, Barbara Sherry, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD PhD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD

Blood (2014) 124 (21): 1948.

https://doi.org/10.1182/blood.V124.21.1948.1948

Published: 2014

Journal Articles

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Holbrook E. Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E. M. Herman, Jonathon P. Butchar, Carolyn Cheney, Xiaoli Zhang, Joseph J. Buggy, Natarajan Muthusamy, Ronald Levy, Amy J. Johnson, John C. Byrd

Blood (2014) 123 (12): 1957–1960.

https://doi.org/10.1182/blood-2014-01-547869

Published: 2014

Journal Articles

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert, Matthew R. Stefanovski, Virginia M. Goettl, Kelly A. Smucker, Lisa L. Smith, Jason A. Dubovsky, William H. Towns, Jessica MacMurray, Bonnie K. Harrington, Melanie E. Davis, Stefania Gobessi, Luca Laurenti, Betty Y. Chang, Joseph J. Buggy, Dimitar G. Efremov, John C. Byrd, Amy J. Johnson

Blood (2014) 123 (8): 1207–1213.

https://doi.org/10.1182/blood-2013-07-515361

Published: 2014

Includes: Supplemental data

Journal Articles

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment

Carsten U Niemann, MD, PhD, Angelique Biancotto, PhD, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, J. Philip McCoy, Jr., Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 2856.

https://doi.org/10.1182/blood.V122.21.2856.2856

Published: 2013

Journal Articles

Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia

Ekaterina Kim, MS, Stefan Koehrer, MD, Nathalie Y. Rosin, PhD, Zhiqiang Wang, Ph.D., Deborah A. Thomas, MD, Farhad Ravandi, MD, Steven M. Kornblau, MD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Zeev Estrov, MD, Joseph J. Buggy, PhD, Markus Muschen, MD, PhD, Richard E. Davis, MD, Jan A. Burger, MD, PhD

Blood (2013) 122 (21): 1399.

https://doi.org/10.1182/blood.V122.21.1399.1399

Published: 2013

Journal Articles

Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab

Julia Hoellenriegel, Elena Hartmann, MD, PhD, Andreas Rosenwald, MD, Susan O'Brien, MD, Michael Keating, MD, William G. Wierda, MD, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD, PhD

Blood (2013) 122 (21): 1631.

https://doi.org/10.1182/blood.V122.21.1631.1631

Published: 2013

Journal Articles

Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Holbrook E Kohrt, MD, PhD, Idit Sagiv-Barfi, PhD, Sarwish Rafiq, MS, Sarah E.M. Herman, Jonathan P Butchar, Ph.D., Carolyn Cheney, B.S, Xiaoli Zhang, PhD, MS, Joseph J. Buggy, PhD, Natarajan Muthusamy, DVM, Ph.D, Ronald Levy, MD, Amy J Johnson, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 373.

https://doi.org/10.1182/blood.V122.21.373.373

Published: 2013

Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Blood (2013) 122 (15): 2539–2549.

https://doi.org/10.1182/blood-2013-06-507947

Published: 2013

Includes: Supplemental data

Journal Articles

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, Laurence Elias

Blood (2013) 122 (14): 2412–2424.

https://doi.org/10.1182/blood-2013-02-482125

Published: 2013

Includes: Supplemental data

Journal Articles

In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial

Julia Hoellenriegel, Susan O'Brien, MD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 186.

https://doi.org/10.1182/blood.V120.21.186.186

Published: 2012

Journal Articles

Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL

Mariela Sivina, PhD, Robert J. Kreitman, MD, Evgeny Arons, PhD, Joseph J. Buggy, PhD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 1802.

https://doi.org/10.1182/blood.V120.21.1802.1802

Published: 2012

Journal Articles

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Jennifer A. Woyach, MD, Matthew R Stefanovski, B.S., Virginia Goettl, Amy S. Ruppert, MAS, Kelly A Smucker, Lisa L. Smith, Jason A Dubovsky, Ph.D, William H. Towns, Jessica MacMurray, Melanie E. Davis, Yicheng Mao, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, John C. Byrd, MD, Amy J Johnson, PhD

Blood (2012) 120 (21): 183.

https://doi.org/10.1182/blood.V120.21.183.183

Published: 2012

Journal Articles

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Jan A. Burger, MD, PhD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Julia Hoellenriegel, Alessandra Ferrajoli, M.D., Stefan Faderl, MD, Susan Lerner, MS, Gracy Zacharian, Xuelin Huang, PhD, Danelle F. James, M.D., Joseph J. Buggy, PhD, Hagop M Kantarjian, Susan M. O'Brien

Blood (2012) 120 (21): 187.

https://doi.org/10.1182/blood.V120.21.187.187

Published: 2012

Journal Articles

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Ravi Vij, MD, Betty Y. Chang, PhD, Jesus G. Berdeja, MD, Carol Ann Huff, M.D., Nikoletta Lendvai, MD PhD, Yu-Tzu Tai, PhD, Stella Chang, Davina Moussa, Joseph J. Buggy, PhD, Laurence Elias, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 4039.

https://doi.org/10.1182/blood.V120.21.4039.4039

Published: 2012

NARROW

Highly Selective Irreversible ITK Inhibitor Cpi-818 Reduces Acute Graft-Versus Host Disease

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

In Vivo Evidence That Ibrutininb Deregulates Chemokine Receptor CXCR4 Surface Membrane Expression and Signaling, Along with Inhibiting B Cell Antigen Receptor Signaling, As Causes for Defective Homing and Impaired Retention of CLL Cells in Tissues

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment

Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia

Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab

Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial

Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only